💰 Biocon Expects Stronger FY27 Performance, Sees Momentum
Published by OOPSONLINE.IN · Source: Devdiscourse · 1 min read · · Updated
What actually happened
Biocon expects to deliver a stronger performance as FY27 progresses, with growth momentum set to accelerate during the year and a meaningful pickup in the second half for its biosimilars business, according to the company's management commentary in its Q1 FY27 investor presentation released on Thursday. The company also said it does not expect any material increase in competitive intensity in its generics business.
Key points
- Biocon expects to deliver a stronger performance as FY27 progresses, with growth momentum set to accelerate during the year and a meaningful pickup in the second half for its biosimilars business, according to the company's management commentary in its Q1 FY27 investor presentation released on Thursday.
- The company also said it does not expect any material increase in competitive intensity in its generics business.
Summary based on data provided by Devdiscourse. Full article available at the original publisher.
- #business
- #biocon
- #expects